Our Pipeline

The IMA’s thriving pipeline of projects includes projects aimed at prototyping innovative medicines and vaccines (Drug and Vaccine Prototyping) as well projects aimed at studying human patients (Experimental Human Biology). Representative projects include those in the pipeline below.

Q

Drug and Vaccine Prototyping

The Drug and Vaccine Prototyping arm helps Stanford faculty convert their scientific discoveries into high-quality drug and vaccine prototypes. Such prototypes will be embraced by industry because they reduce the therapeutic risk inherently associated with new biology while rapidly identifying those discoveries that have the best chance of improving patient care. Prototyping on this scale has never been attempted in an academic setting before.

Q

Experimental Human Biology

The Experimental Human Biology arm helps lab researchers leverage Stanford’s hospitals and clinics to gain access to critical data and/or reagents to test the therapeutic potential of their scientific hypotheses and discoveries more rapidly. Patient-facing research is especially crucial in the development of treatments for emerging or rare diseases.

Click on a project title below for more details.

Select a Research Arm:

Filter By:

Project Title

Partnered

Lead ID

Lead Optimization

IND-Enabling

Small Molecule Therapeutics

Cell / Gene Therapies

Protein Therapeutics

Clinical Studies

Theranostic TG2 inhibitor for celiac disease

View Post

A cell-selective therapy for neuroendocrine tumors

True
View Post

Fluoxetine analog for glioblastoma therapy

True
View Post

Mutant-selective inhibitor for JAK2-dependent cancers

View Post

Novel therapeutic for Parkinson’s disease

True
View Post

Chloride channel inhibitor for hyponatremia

View Post

MDA5 antagonist for autoimmune diseases

View Post

RARalpha antagonist for neuropathic pain prevention

View Post

BMP synthase activator for neurodegeneration

View Post

CRISPR-corrected esophageal cell therapy for epidermolysis bullosa

View Post

Gene editing for HIV

View Post

NMNAT2 AAV gene therapy for glaucoma

View Post

AAV gene therapy for chronic pain

View Post

Broad-spectrum coronavirus antibody

View Post

CNTN2 selective antibody-guided cardiac surgery

View Post

Reversal agent for T-cell depleting antibodies

View Post

Chemokine receptor antagonist for glioblastoma therapy

True
View Post

ISM1 derivative for NASH therapy

View Post

Our pipeline embraces projects founded on four essential criteria

Solving an Unmet Medical Need

Solutions with potential to address pressing medical gaps.

First-in-Class Potential

Direct pathways to novel, pioneering medicines.

Highly Differentiated

Capacity to introduce innovative approaches across disease spectrums.

Leveraging Expertise

Builds upon the deep expertise of Stanford’s scientists and physicians.

Success Stories

Projects supported by the IMA have the potential to transform medicine. Learn about some of the products that exited our pipeline.